# SIRT With Tremelimumab and Durvalumab for Resectable HCC

> **NCT05701488** · PHASE1 · RECRUITING · sponsor: **Jiping Wang, MD, PhD** · enrollment: 20 (estimated)

## Conditions studied

- Resectable Hepatocellular Carcinoma
- Hepatocellular Carcinoma
- Hepatocellular Cancer

## Interventions

- **DRUG:** Durvalumab
- **DRUG:** Tremelimumab
- **DEVICE:** SIRT

## Key facts

- **NCT ID:** NCT05701488
- **Lead sponsor:** Jiping Wang, MD, PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-21
- **Primary completion:** 2026-10-01
- **Final completion:** 2026-10-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-09-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05701488

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05701488, "SIRT With Tremelimumab and Durvalumab for Resectable HCC". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05701488. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*